LDLR and obesity disorder: Saroglitazar treatment (2 and 4 mg/kg/day, PO) showed improvement in hepatic LDLR protein levels which indicates that saroglitazar may inhibit hepatic LDLR degradation mediated by MSG, together leading to improvement in lipid homeostasis and amelioration of obesity and obesity-associated systemic inflammation.